Debut builds an AI-driven ingredient discovery platform to create scientifically-discovered, clinically-proven biotech ingredients and customizable formulations for skincare. The platform can screen upward of 50 billion ingredients and focuses on novel chemical entities that target the 14 hallmarks of aging. Debut's proprietary in-house skin health datasets have achieved 99% data consistency versus 85% in public datasets, improving its predictive capabilities. The company enables beauty brands to outsource formulation innovation at scale, reducing upfront R&D expenses. Debut plans to scale its formulation business in the US and enter Asia beginning in Singapore through partnerships with leading brands. Named one of TIME100 Most Innovative Companies 2025, Debut recently secured $20M to accelerate platform development and commercial expansion. Debut is a vertically integrated synthetic biology company based in San Diego, CA, focused on producing bio-based fragrance and cosmetic bioactive ingredients. Led by founder and CEO Joshua Britton, Ph.D., the company operates an integrated synthetic biology platform and advanced biomanufacturing approaches. Its platform aims to replicate the scent signature and precise characteristics of natural ingredients, including structurally complex and trace compounds that are difficult to source. Debut's advanced biomanufacturing is intended to enable fragrance brands to transition to bio-based formulas while protecting the olfactive integrity of their products. The company plans to use the funds to accelerate development of bio-identical and novel fragrance molecules, opening new creative possibilities for the fragrance industry. Debut Biotech has developed a proprietary cell-free biomanufacturing platform to produce rare, high-value and novel compounds and to improve traditional ingredient manufacturing. The platform has applications across food and wellness products, cosmetics, colors, therapeutics and other industrial uses. The company plans to commercialize ingredients developed on its platform using proceeds from the recent financing. To scale commercialization, Debut will expand into a 26,000 square foot facility in San Diego and triple the size of its team across San Diego and Atlanta. Those facility investments are intended to enable manufacturing to be done entirely in the United States. The company is led by CEO Joshua Britton. Debut Biotechnology develops a cell‑free biomanufacturing platform that combines custom‑designed immobilized enzymes with continuous processes to produce high‑value molecules for pharmaceutical and specialty chemical customers. Its plug‑and‑play enzyme cartridges enable transformation of bio‑renewable materials into therapeutics and specialty chemicals. The company has partnered with two large manufacturers to integrate its platform into existing pipelines. Debut plans to use new funding to support those integrations, expand business development, double its science team and create a pilot production system. The company was founded by Joshua Britton, Greg Wess and Brady Beauchamp and is a UC‑Irvine spinout.

Total raised

$85M

Funding rounds

4

Latest round

Equity

Latest activity

Aug 2025